National Institutes of Health

InVivo Biosystems specializes in utilizing non-mammalian model organisms for biological and biomedical research. The company has developed a proprietary transgenic platform that allows for the genetic modification of simple microscopic animals, such as C. elegans and zebrafish, to serve as human proxies in disease research and drug discovery. This innovative approach provides researchers with valuable insights into genetic mutations and human health. By offering custom genome-edited models, InVivo Biosystems supports pharmaceutical, nutraceutical, and biotechnology companies, as well as academic institutions, in accelerating their research and drug development initiatives. The company aims to make research more affordable and accessible, ultimately contributing to the exploration of treatments for significant health challenges, including Alzheimer's disease, epilepsy, and cancer.

Lucid Diagnostics is a commercial-stage, cancer-prevention medical diagnostics company. Lucid focuses on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test is performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, a diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

Tiziana Life Sciences is a clinical-stage biotechnology company based in the United Kingdom, dedicated to the discovery and development of innovative therapies targeting diseases in oncology and immunology. The company's product pipeline features Foralumab, a human anti-CD3 monoclonal antibody aimed at treating various autoimmune and inflammatory conditions, including graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently in phase II clinical trials for epithelial thymic carcinoma and has potential applications in hepatocellular carcinoma. Additionally, Tiziana develops Anti IL-6r, a monoclonal antibody for treating severe respiratory symptoms in hospitalized COVID-19 patients, and StemPrintER, a multi-gene assay designed for patients with specific types of breast cancer. Founded in 2013, Tiziana Life Sciences operates with a focus on advancing transformative therapies for challenging medical conditions.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Metabolon, Inc. is a health technology company specializing in metabolomics, which focuses on the analysis of metabolites to aid in disease detection and precision medicine. The company develops a range of clinical diagnostic tests, including QUANTOSE IR for early-stage insulin resistance and Meta IMD for identifying metabolites linked to inherited metabolic disorders. Metabolon also offers customizable research services and multiomics solutions, enabling academic and commercial researchers to explore various life sciences areas effectively. The company's technologies address a wide array of health conditions, including cardiovascular issues, diabetes, and cancer, and are utilized across sectors such as biotechnology, pharmaceuticals, and nutrition. Founded in 2000 and headquartered in Morrisville, North Carolina, Metabolon has a global presence, including offices in Munich, London, Madrid, and China, and maintains strategic partnerships with major firms in the pharmaceutical and consumer health industries.

Matter Bio is a biotechnology company dedicated to preserving genome integrity and enhancing longevity through the preservation of DNA information. The company aims to address the critical issue of information loss in the genome by assembling a team of expert scientists and executives. By focusing on mutation reversal, Matter Bio seeks to empower patients with the potential to improve their health and extend their lifespan. Through its innovative research services, the company strives to advance the understanding and application of genetic preservation techniques.

Selsym Biotech is a biotechnology company focused on developing innovative therapies aimed at controlling bleeding in trauma and surgical situations. The company's flagship product, Hemostatic Healing Hydrogels (H3), offers a novel solution to address critical challenges in hemorrhage control, particularly in light of ongoing platelet supply shortages and limitations related to shelf life. By providing effective platelet-mimetic therapies, Selsym Biotech seeks to revolutionize the management of uncontrolled bleeding, enhancing outcomes for patients in emergency and surgical settings.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Lamassu Pharma is a biotech startup dedicated to addressing the significant unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown promising preclinical results in significantly reducing both mortality and morbidity associated with this condition. This therapeutic candidate, developed by leading scientists at Mayo Clinic, aims to improve medical outcomes for patients suffering from acute pancreatitis. Lamassu Pharma is currently advancing the development of this compound through safety testing, preparing for future clinical trials with the ultimate goal of saving lives and enhancing treatment options for those affected by this serious disease.

Maxim Biotech provides vitro diagnostic testing development and testing solutions.

AcuraStem Inc is a biotechnology company, founded in 2016 and based in Monrovia, California, that focuses on developing a precision medicine platform aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The company utilizes complex cellular models derived from ALS patients to evaluate disease progression and test existing FDA-approved therapeutics and their combinations. By employing advanced cellular reprogramming and artificial intelligence technologies, AcuraStem seeks to transform the standard of care for neurodegenerative diseases, enabling drug discovery companies to assess their therapeutic candidates more effectively. The team comprises experts, including PhDs, professors, and experienced professionals from the pharmaceutical industry, all dedicated to finding innovative treatments for this challenging health issue.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

InVivo Biosystems specializes in utilizing non-mammalian model organisms for biological and biomedical research. The company has developed a proprietary transgenic platform that allows for the genetic modification of simple microscopic animals, such as C. elegans and zebrafish, to serve as human proxies in disease research and drug discovery. This innovative approach provides researchers with valuable insights into genetic mutations and human health. By offering custom genome-edited models, InVivo Biosystems supports pharmaceutical, nutraceutical, and biotechnology companies, as well as academic institutions, in accelerating their research and drug development initiatives. The company aims to make research more affordable and accessible, ultimately contributing to the exploration of treatments for significant health challenges, including Alzheimer's disease, epilepsy, and cancer.

RNAConnect provides enzymatic tools for visualizing and manipulating RNA.

Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, that specializes in developing innovative therapeutics for neurodegenerative diseases and other conditions with unmet medical needs. The company has created a novel drug platform known as Clean-Surface Nanosuspension, which enables the production of clean-surface nanocrystal medicines. This technology supports a pipeline of new drug candidates, particularly targeting demyelinating disorders and oncology. Founded in 2012, Clene Nanomedicine aims to advance treatment options through its unique approach to drug development.

Integral Molecular, Inc. is a biotechnology company based in Philadelphia, Pennsylvania, specializing in the development of innovative technologies to aid drug discovery for diseases such as cancer, HIV, and arthritis. The company offers the Lipoparticle technology, which facilitates the identification and optimization of drug candidates targeting integral membrane proteins. With over 20 years of experience in the field, Integral Molecular has supported more than 400 companies in their research efforts, medication discovery, and vaccine development. Its products play a crucial role throughout the drug discovery process, particularly in the development of antibodies and chemical compounds targeting challenging protein targets.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years. their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing.

South Rampart Pharma is a clinical-stage life science company dedicated to developing safe and effective pain relief alternatives. The company focuses on synthesizing and characterizing new non-opioid and non-liver toxic molecules that target pain signaling pathways in the brain's periaqueductal grey (PAG) region. Its lead candidate, SRP-001, has received U.S. FDA Fast Track designation for acute pain treatment. This candidate aims to influence pain-related genes through various biological pathways, including endocannabinoid signaling and mechanical nociception, providing a promising solution to mitigate the risks associated with traditional pain medications, particularly their potential for abuse.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

North Carolina A&T State University is so many things to so many people, both in our state and around the country. North Carolina A&T State University is an HBCU. We are a top-flight research university, the largest historically black university (HBCU) in the country, the #1 producer of degrees awarded to African Americans in North Carolina and nationally recognized or our excellence in science, technology, mathematics and engineering (STEM) education. We are a diverse community, bound by intense pride and tradition, with fiercely loyal alumni who hold positions of importance and influence in companies and government agencies across the state, the country and the world. We are achievers, driven by a curious, limitless, fearless spirit that fuels discovery and innovation, resulting in 41 patents issued based on our research, as well as numerous spin-off and start-up companies. We are inclusive and welcoming, with students from many backgrounds and cultures, every part of our state, our nation and countries around the globe. We are passionate, driven by a desire to do more, be more and make more of a difference. Since we opened our doors in 1892, we have focused on giving every student the hands-on opportunities, core knowledge and global perspective that will lead them to make real and lasting change in their lives and the lives of others. At N.C. A&T, we have so much to be proud of, and you can learn more about those "Points of Pride" here. You can also use the links below to learn more about what makes N.C. A&T unique, from our leadership and history to our many rankings and recognitions.

Nexilico, Inc. is an early-stage biotechnology company based in Albany, California, specializing in precision medicine and microbiome research and development. Founded in 2017, the company focuses on creating advanced predictive computational platforms to enhance drug design and development processes. By pioneering next-generation in silico microbiome technologies, Nexilico aims to deepen the scientific understanding of microbiomes and their impact on health and disease. This knowledge is leveraged to create innovative microbiome-based solutions that improve therapeutic outcomes for various medical treatments.

Curi Bio is a biotechnology company dedicated to enhancing drug discovery and development through innovative technologies that leverage human stem cells, systems biology, and data analytics. The company aims to streamline the identification and development of new medicines by providing advanced biosystem platforms that integrate human cells and data. Curi Bio's technology offers a range of products designed for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research. By enabling in vivo maturation and alignment of various cell types, the company allows drug developers to conduct more accurate safety and efficacy tests on new drug candidates, ultimately fostering the advancement of next-generation human medicines.

Applied BioMath helps biotechnology and pharmaceutical companies accelerate and de-risk drug research and development. Its goal is to reduce late-stage attrition by applying advanced mathematical and systems biology techniques at critical decision points in the drug discovery process. They accomplish this by employing internally developed algorithms where systems approach naturally drive quantitative decisions to provide customers with a thorough understanding of the optimal way forward with their drug discovery efforts. Through high-performance computational biology and large dataset analyses, their predictive models provide best-in-industry insight allowing our customers to realize the most cost-effective method for drug discovery. The company was founded in 2013 by Dr. John Burke, Dr. Joshua Apgar, and Andrew Sutherland.

Access to Advanced Health Institute is a nonprofit biotech research institute that brings together specialists, technologies, and platforms to offer accessible goods and solutions for leveraging the immune system to alleviate disease.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Pulvinar Neuro is a neurotechnology company focused on advancing neuroscience research by providing innovative and affordable products. The company aims to support both basic and translational neuroscience efforts, utilizing the latest technologies to facilitate groundbreaking research. By offering cutting-edge tools and resources, Pulvinar Neuro enables brain researchers to explore new insights and develop solutions that can significantly impact the field of neuroscience.

Sensor-Kinesis Corp. (“SKC”) is a development stage hi-tech company that is developing proprietary, flexible micro biosensor integrated computer chips suitable for printing on many surfaces. These chips which detect certain biomolecules can be linked to smart devices and shared via cloud technology. SKC’s chips are being developed to detect and measure biological signals and data from humans and then use smart devices to transmit the information for analysis and storage. The application for this technology is both universal and versatile across entire industries including healthcare, infectious disease, food safety, pharmaceuticals, medical devices, agriculture, laboratories, biodefense, and transportation. The company's goal is to provide a proprietary innovation that will allow physicians, health and safety organizations, and individuals the ability to detect diseases and other detractors to our health and well-being at a lower limit-of-detection in a single portable low-cost device.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

The Indiana CTSI is dedicated to leveraging and strengthening the state’s life sciences community to achieve better health for people in Indiana.Leadership and staff at the Indiana CTSI are working to develop the best processes and resources to enable the efficient translation of scientific discoveries to patient care.Indiana CTSI programs and partnerships are designed to educate, attract and retain top research talent in the state for generations to come.

Chemeleon has developed an innovative diagnostic platform that provides rapid, accurate, and affordable detection of a wide array of analytes, including drugs, proteins, and viruses. This proprietary in vitro diagnostic technology delivers a colorimetric readout within minutes, visible to the naked eye, without requiring reagents, instruments, or specialized training. This capability facilitates decentralized testing, allowing clinicians to extend point-of-care diagnostics and enabling individuals to self-administer tests at the point of need. By combining selective molecular receptors with colorimetric nanomaterial reporters, Chemeleon's diagnostics offer immediate and actionable results, significantly improving patient outcomes while reducing costs. Notably, under a National Institutes of Health grant, the company created a test to detect beta-2-transferrin, aiding healthcare providers in promptly diagnosing cerebrospinal fluid leaks, which can drastically lower morbidity and patient stay duration. This technology meets the World Health Organization's ASSURED criteria, making it suitable for both advanced healthcare settings and resource-limited environments, thereby revolutionizing the accessibility of critical diagnostic services.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Cellular Logistics, Inc. is a biotechnology company founded in 2016 and based in Madison, Wisconsin. The company specializes in developing an acellular biomaterial that serves as a stand-alone therapeutic for cardiac and tissue vascularization applications. This innovative biomaterial aims to significantly enhance cell survival rates and retention in regenerative medicine therapeutics. It also functions as a delivery mechanism for these therapies, improving post-injection cell retention and ultimately benefiting patients undergoing regenerative treatments.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Texas Biomedical Research Institute, founded in 1941 by Thomas B. Slick Jr., is a prominent research institution based in San Antonio, Texas. Its mission is to advance understanding of chronic and infectious diseases through innovative research and the application of cutting-edge technologies. The Institute is recognized globally for its high-quality scientific contributions and aims to protect families and the broader community from the threats posed by infectious diseases. By fostering a collaborative environment for researchers, Texas Biomedical Research Institute continues to make significant strides in the fields of biomedical science and public health.

Neurovations, a patient care and innovation company, was founded in 1992 by CEO Dr. Eric Grigsby. Today, Neurovations is a national leader in medical device and pharmaceutical innovation, clinical research, and a world-class education program focusing in pain and neuroscience. Dr. Grigsby is deeply connected to the healthcare community through our non-profit HealthRoots Foundation. Our unwavering mission is to inspire hope and to contribute to the health and well-being of our patients and communities through integrated clinical practice, research, and education.

The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners - Morehouse School of Medicine (MSM), Georgia Institute of Technology (Georgia Tech), and the University of Georgia (UGA) - to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide. Emory is a national leader in healthcare and biomedical research as well as an outstanding leader in clinical and translational research training and education. Morehouse School of Medicine is a nationally recognized historically black institution that brings ethnic diversity to biomedical research, addresses health disparities through successful community engagement research, and serves as a pipeline for training minority researchers. Georgia Tech is a national leader in biomedical engineering and the application of innovative systems engineering to healthcare solutions. UGA has a proven track record in outstanding basic and translational research and, as the State’s land-grant institution, offers a robust statewide network that enhances community outreach, service, and research. These institutions extend their current partnerships in healthcare, education, and cutting-edge interdisciplinary research to synergize Georgia CTSA. Created in 2017 as one of a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences, part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA), shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts and train the next generation of clinical investigators.

Stemloop is a biotechnology company focused on developing innovative cell-free biosensing products that enhance chemical and molecular testing processes. By utilizing genetically encoded sensing and response mechanisms, Stemloop creates accessible and actionable biosensors that are faster, cheaper, and easier to use than traditional laboratory tests. The company's mission is to address unmet needs in chemical sensing and detection, enabling medical professionals to deliver accurate and timely test results at reduced costs. Through its novel technology, Stemloop aims to unlock the potential of biology to respond effectively to various global challenges.

Wake Forest School of Medicine, located in Winston-Salem, North Carolina, is an esteemed educational institution founded in 1902, focusing on biomedical research and primary care education. The school offers students hands-on experience with patients from the first week of medical school, emphasizing practical training alongside academic learning. With a nationally recognized research program, Wake Forest School of Medicine has secured over $400 million in extramural funding, supporting its mission to advance medical knowledge and care. The institution educates nearly 1,900 students and fellows, including physicians, basic scientists, and allied clinical professionals, preparing them for a range of careers in the medical field.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on utilizing artificial intelligence to decode the human immune system and develop innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary AI-immunology technology to create a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies—two of which are in Phase I/IIa clinical trials. In addition to its cancer treatments, Evaxion is also advancing a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program targeting Methicillin-resistant Staphylococcus aureus currently in preclinical development. By combining AI with immunology, Evaxion seeks to improve therapeutic efficacy for patients with unmet medical needs.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Eliaz Therapeutics has developed a patented medical device that selectively removes galectin-3 from human blood, addressing currently untreatable life-threatening diseases. This device targets galectin-3, a protein associated with conditions such as diabetes, chronic kidney disease, organ fibrosis, and cancer. By employing a single-use apheresis column that utilizes a proprietary capturing molecule, the device effectively eliminates both bound and free galectin-3 from circulation. This innovative approach offers a less invasive treatment option with fewer side effects compared to traditional therapies, enabling physicians to provide effective care for patients suffering from acute kidney injury, sepsis, and other inflammatory and fibrotic diseases. The device is designed for easy integration into existing hospital practices, enhancing its potential for widespread adoption.

Ramona develops advanced microscopy tools designed to enhance cellular-level research by capturing detailed images over vast areas. The company's innovative microscope employs custom control electronics to efficiently process large volumes of image data from multiple micro-cameras, allowing researchers to capture and analyze extensive gigapixel datasets. This capability not only provides a wider field of view but also enables synchronous data capture, allowing for real-time observation of cellular processes. By offering a new perspective on cellular dynamics, Ramona's technology empowers researchers to make more informed decisions quickly and effectively.

Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.

Reliant Glycosciences is a biotechnology company focused on developing diagnostic and prognostic tools for patients with IgA nephropathy.

AVM Biotechnology LLC is a clinical-stage regenerative medicine company based in Seattle, Washington. Founded in 2008, it specializes in the discovery, development, and commercialization of stem cell technologies for applications in regenerative medicine, oncology, and human biologics. The company offers a range of innovative compounds aimed at enhancing organ regeneration and immune system recovery through the modulation of stem cell binding. Its platforms include Boutique Biologics, which focuses on personalized medicine by creating patient-specific biologics that minimize immunogenicity, and Better Biologics, which enables large-scale production of human biologics that address resistance issues. AVM's lead drug, AVM0703, is an advanced formulation of dexamethasone designed to activate the body’s immune cells against cancer, autoimmunity, and infectious diseases. The company is supported by a Scientific Advisory Board comprised of experts in cancer and immunology, and it is engaged in various preclinical development projects, including small molecules and antibody-based candidates.

Datirium offers a scientific data analysis web platform known as SciDAP, designed to facilitate the integration and analysis of Next Generation Sequencing (NGS) data for biologists. The platform aims to enhance collaboration between biologists and bioinformaticians by providing user-friendly, push-button analysis tools alongside options for advanced customization. SciDAP presents analytical data in a visually accessible format, enabling biologists to quickly comprehend complex concepts and identify new patterns. It also allows users to delve deeper into the data through interactive charts and graphs, promoting a more thorough understanding. By enabling biologists to perform analyses independently and automate routine tasks, Datirium's platform bridges the gap between scientific research and data management.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

NYU Langone Health is a nonprofit academic medical center located in New York City, renowned for its commitment to patient-centered care, medical education, and research. It offers a comprehensive range of services, diagnosing and treating various conditions including lung diseases, joint and muscle disorders, neurological disorders, blood disorders, and gastrointestinal issues. As a center of excellence, NYU Langone Health integrates clinical care with cutting-edge research and education, ensuring high-quality healthcare for its patients while advancing medical knowledge and practices.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative treatments for various central nervous system (CNS) disorders, including multiple sclerosis, spinal cord injury, glaucoma, and stroke. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases using novel science centered on lipoprotein receptors. Novoron is advancing a pipeline of pre-clinical therapies aimed at addressing conditions such as Alzheimer's disease, tauopathies, and demyelinating diseases, with the goal of offering effective treatments for conditions that currently lack viable options. The company's research emphasizes repairing damage to the brain and spinal cord, ultimately striving to enhance recovery for patients suffering from debilitating neurological conditions.

Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.

HQ Science is a biotechnology company at the forefront of molecular diagnostics innovation.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases. The company has a diverse pipeline that includes gene therapy programs for rare genetic disorders and various chimeric antigen receptor (CAR) T cell therapies targeting both hematologic malignancies and solid tumors. Notable projects include MB-107, a gene therapy aimed at treating X-linked severe combined immunodeficiency, which is currently undergoing Phase 1/2 clinical trials. Other therapies under development include MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and multiple CAR T programs targeting glioblastoma, prostate cancer, and pancreatic cancer. Mustang Bio also collaborates with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center for research and development in gene editing and oncolytic viruses. Established in 2015 and headquartered in New York, Mustang Bio operates as a subsidiary of Fortress Biotech, Inc.

The Los Angeles Biomedical Research Institute (LA BioMed) is a 501(c)3 independent non-profit biomedical research organization that was founded in 1952. The Institute has over more than 120 principal investigators and 400 researchers in total — MD’s, MD/PhD’s, and PhD’s — working on over 1,000 research studies. They are academically affiliated with the David Geffen School of Medicine at UCLA and work in partnership with the Harbor-UCLA Medical Center. Their research is funded by many sources including: grants from the NIH and other government entities, Industry and teaching contracts and royalties, as well as private donors and other non-profit foundations.

Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

ThermoGenesis Holdings, Inc. is a healthcare company that develops and commercializes automated technologies for cell-based therapies and bioprocessing. The company provides a range of solutions tailored for clinical biobanking, point-of-care applications, and immuno-oncology automation. Notable products include the CAR-TXpress platform, which enhances the manufacturing process for CAR-T immunotherapy, and the AXP Automated Cell Separation System, designed for isolating stem and progenitor cells from umbilical cord blood. Additionally, ThermoGenesis offers the BioArchive Automated Cryopreservation System for the robotic storage of cord blood samples and other cell therapeutic products. The PXP Point-of-Care System enables the automated processing of autologous stem cells at surgical centers or clinics. Other products in development include X-Series systems for cell isolation, washing, purification, and large-scale cell processing using proprietary buoyance-activated cell sorting technology. Founded in 1986 and headquartered in Rancho Cordova, California, the company was previously known as Cesca Therapeutics Inc. before rebranding in November 2019.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative treatments for various central nervous system (CNS) disorders, including multiple sclerosis, spinal cord injury, glaucoma, and stroke. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases using novel science centered on lipoprotein receptors. Novoron is advancing a pipeline of pre-clinical therapies aimed at addressing conditions such as Alzheimer's disease, tauopathies, and demyelinating diseases, with the goal of offering effective treatments for conditions that currently lack viable options. The company's research emphasizes repairing damage to the brain and spinal cord, ultimately striving to enhance recovery for patients suffering from debilitating neurological conditions.

Hesperos, Inc. specializes in the development of Human-on-a-Chip microfluidic systems aimed at transforming toxicology testing and drug discovery efficacy evaluations. Founded by Michael L. Shuler and James J. Hickman, the company focuses on creating pumpless platforms that utilize serum-free cellular mediums to facilitate communication between multi-organ systems. Their innovative technology incorporates integrated computational pharmacokinetics and pharmacodynamics modeling, allowing for live physiological response assessments through functional readouts from various tissues, including neurons, cardiac, muscle, and barrier tissues, as well as the liver and pancreas. This approach enables clients to predict in vivo functions without relying on animal models, advancing the field of biomedical research.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Ramona develops advanced microscopy tools designed to enhance cellular-level research by capturing detailed images over vast areas. The company's innovative microscope employs custom control electronics to efficiently process large volumes of image data from multiple micro-cameras, allowing researchers to capture and analyze extensive gigapixel datasets. This capability not only provides a wider field of view but also enables synchronous data capture, allowing for real-time observation of cellular processes. By offering a new perspective on cellular dynamics, Ramona's technology empowers researchers to make more informed decisions quickly and effectively.

HDT Bio is a clinical-stage biotechnology company focused on developing RNA vaccines and therapeutics to combat infectious diseases and cancer. Utilizing its innovative LION formulation technology, the company creates ribonucleic acid-based products that enhance the delivery and stability of nucleic acids through various administration routes. HDT Bio’s offerings include self-amplifying RNA vaccines and innate immune agonist therapeutics, which aim to activate innate immunity, amplify adaptive immune responses, and disrupt tumor tight junctions. The company's mission is to advance immunotherapy technologies in a cost-effective manner, addressing critical healthcare needs in both developed and low- to middle-income countries, particularly in the fight against some of the world's most dangerous infectious diseases.

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new platform technology developed by Professor John Rose at Yale University School of Medicine. We are dedicated to creating recombinant and replication proficient-virus like vesicle (VLV)-based vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

GenNext Technologies is a platform that provides instrumentation, software, and services to structural biology researchers within the biopharmaceutical industry.

Visikol is a CRO focused on advanced drug discovery that is leading the field of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

PhagePro is an early-stage biotechnology therapeutics company focused on developing bacteriophage-based products aimed at preventing bacterial infections, particularly in vulnerable communities worldwide. By offering innovative alternatives for disease prevention, PhagePro seeks to control outbreaks in both clinical and community settings. Its products play a crucial role in addressing public health challenges, helping to prevent fatal diseases such as cholera and enhancing overall health outcomes.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Datirium offers a scientific data analysis web platform known as SciDAP, designed to facilitate the integration and analysis of Next Generation Sequencing (NGS) data for biologists. The platform aims to enhance collaboration between biologists and bioinformaticians by providing user-friendly, push-button analysis tools alongside options for advanced customization. SciDAP presents analytical data in a visually accessible format, enabling biologists to quickly comprehend complex concepts and identify new patterns. It also allows users to delve deeper into the data through interactive charts and graphs, promoting a more thorough understanding. By enabling biologists to perform analyses independently and automate routine tasks, Datirium's platform bridges the gap between scientific research and data management.

Abterra Biosciences specializes in antibody discovery and sequencing services aimed at enhancing therapeutic antibody development. The company utilizes advanced technologies, including next-generation sequencing, mass spectrometry, and machine learning, to analyze antibody responses and rapidly identify high-affinity therapeutic antibodies. Its innovative platform, Alicanto, streamlines the discovery process by identifying target-specific antibodies directly from serum, eliminating the need for traditional and time-consuming methods such as cell selection and cloning. By combining the expertise of data scientists and biologists, Abterra Biosciences aims to provide healthcare researchers with new insights and efficient solutions in the field of antibody therapeutics.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Abterra Biosciences specializes in antibody discovery and sequencing services aimed at enhancing therapeutic antibody development. The company utilizes advanced technologies, including next-generation sequencing, mass spectrometry, and machine learning, to analyze antibody responses and rapidly identify high-affinity therapeutic antibodies. Its innovative platform, Alicanto, streamlines the discovery process by identifying target-specific antibodies directly from serum, eliminating the need for traditional and time-consuming methods such as cell selection and cloning. By combining the expertise of data scientists and biologists, Abterra Biosciences aims to provide healthcare researchers with new insights and efficient solutions in the field of antibody therapeutics.

Coral Genomics, Inc. is a biotechnology company based in San Francisco, California, founded in 2018. The company specializes in optimizing drug development and deployment through the use of genomic data derived from patients. Coral Genomics focuses on creating new clinical tests that assist healthcare providers in streamlining prior authorization processes and selecting effective medications tailored to individual patients, particularly those with autoimmune conditions such as Inflammatory Bowel Disease and Rheumatoid Arthritis. Additionally, the company has identified a distinct population of non-responder patients and collaborates with drug developers to address their unmet medical needs.

Versiti provides innovative, value-added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases.

Photonic Pharma is an early phase of drug development which uses a game-changing technology platform that combines breakthroughs in fluorescence biosensor engineering and fluorescence lifetime detection in living cells.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.

Armis Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing late-stage clinical products and antimicrobial therapies. Based in Fort Collins, Colorado, the company specializes in non-systemic anti-infective therapeutics aimed at combatting antibiotic resistance and healthcare-associated infections. Its product offerings include Ximycin, a patented localized antimicrobial therapy that provides broad-spectrum coverage against polymicrobial infections at surgical sites, and Veriox, a proprietary platform utilizing peracid technology to treat infections while also promoting positive tissue effects. Armis Biopharma serves various markets, including wound care, orthopedics, and dermatology, and addresses the growing challenges posed by resistant pathogens and chemical/biological threats. The company was incorporated in 1997 and continues to expand its innovative pipeline to meet critical healthcare needs.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

Immusoft Corporation is a biotechnology company based in Seattle, Washington, focused on developing autologous cell therapies for various human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009, the company modifies a patient's immune cells, specifically B cells, to create miniature drug factories that produce gene-encoded medicines, or biologics. By reprogramming these cells, Immusoft's technology enables the in vivo delivery of therapeutics that can replace missing or defective enzymes and proteins. The core ISP technology was initially developed at the California Institute of Technology and is exclusively licensed to Immusoft. This innovative approach aims to improve treatments for rare and infectious diseases by harnessing the body's own immune system.

Aqualung Therapeutics (Aqualung Therapeutics Corporation) leadership are experienced academic leaders, entrepreneurs and translational scientists with expertise in Precision Medicine, who are exploring NAMPT as a key target and novel diagnostic in acute and chronic lung inflammatory disorders. As an organization they are committed to finding novel targets in the treatment of respiratory diseases. Their team is highly skilled at clinical development and they are working collaboratively with the FDA to ensure both acute and chronic respiratory diseases that have significant unmet medical need receive priority review.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Stemloop is a biotechnology company focused on developing innovative cell-free biosensing products that enhance chemical and molecular testing processes. By utilizing genetically encoded sensing and response mechanisms, Stemloop creates accessible and actionable biosensors that are faster, cheaper, and easier to use than traditional laboratory tests. The company's mission is to address unmet needs in chemical sensing and detection, enabling medical professionals to deliver accurate and timely test results at reduced costs. Through its novel technology, Stemloop aims to unlock the potential of biology to respond effectively to various global challenges.